分享:
分享到微信朋友圈
X
综述
心脏磁共振评估肥厚型心肌病二尖瓣装置异常的研究进展
卢嘉慧 杨娜 陈梓娴

Cite this article as: LU J H, YANG N, CHEN Z X. Research advances in CMR for mitral valve apparatus abnormalities in hypertrophic cardiomyopathy[J]. Chin J Magn Reson Imaging, 2026, 17(4): 175-183.本文引用格式:卢嘉慧, 杨娜, 陈梓娴. 心脏磁共振评估肥厚型心肌病二尖瓣装置异常的研究进展[J]. 磁共振成像, 2026, 17(4): 175-183. DOI:10.12015/issn.1674-8034.2026.04.025.


[摘要] 肥厚型心肌病(hypertrophic cardiomyopathy, HCM)是一种由心肌肌小节蛋白基因突变引起的遗传性心肌病,其主要病理生理特征为左心室肥厚和左室流出道梗阻(left ventricular outflow tract obstruction, LVOTO)。尽管室间隔增厚是引起LVOTO的主要解剖学基础,但二尖瓣装置结构和功能异常在梗阻机制与临床症状加重中同样发挥着关键作用,而这一因素在临床实践中却常被低估。心脏磁共振(cardiac magnetic resonance, CMR)凭借其高空间分辨率与多平面成像优势,已成为评估HCM患者二尖瓣装置形态与功能的核心影像学手段。然而,现有综述多集中于CMR在评估HCM整体及心肌组织特征方面的应用,对其在二尖瓣装置异常方面的作用缺乏系统性总结,特别在是形态学改变与LVOTO机制之间关联的深入梳理方面仍存在空白。因此,本文系统梳理了CMR在评估HCM二尖瓣装置异常中的研究进展,分析了当前研究存在的主要问题,并探讨了未来的研究方向,旨在提升临床医生对二尖瓣装置异常的认识,为疾病的早期干预和个体化治疗提供影像学依据。
[Abstract] Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disorder caused by mutations in genes encoding sarcomeric proteins. Its pathophysiological hallmarks include left ventricular hypertrophy and left ventricular outflow tract obstruction (LVOTO). While septal thickening constitutes the primary anatomical basis of LVOTO, structural and functional abnormalities of the mitral valve apparatus play an equally critical role in the obstruction mechanism and symptom exacerbation: a factor often underestimated in clinical practice. Cardiac magnetic resonance (CMR), leveraging its high spatial resolution and multi-planar imaging capabilities, has emerged as a pivotal imaging modality for evaluating the morphology and function of the mitral valve apparatus in HCM patients. However, existing reviews primarily focus on the application of CMR in assessing the overall characteristics and myocardial tissue of HCM, and there is a lack of systematic summaries of its role in mitral valve apparatus abnormalities. In particular, there is still a gap in in-depth analysis of the association between morphological changes and the mechanisms of LVOTO. Therefore, aiming to enhance clinicians' understanding of mitral valve apparatus abnormalities and provide imaging evidence for early intervention and individualized treatment of the disease, this review systematically summarizes recent advances in CMR for assessing mitral valve abnormalities in HCM, analyzes the current research issues, and proposes future research directions, aiming to enhance clinicians' understanding of these anomalies and provide imaging evidence for early intervention and individualized medicine.
[关键词] 肥厚型心肌病;二尖瓣装置;左室流出道梗阻;心脏磁共振;磁共振成像;个体化治疗
[Keywords] hypertrophic cardiomyopathy;mitral valve apparatus;left ventricular outflow tract obstruction;cardiac magnetic resonance;magnetic resonance imaging;individualized medicine

卢嘉慧 1   杨娜 2   陈梓娴 1, 2*  

1 兰州大学第一临床医学院,兰州 730000

2 兰州大学第一医院放射科,兰州 730000

通信作者:陈梓娴,E-mail: chenzxcmr@163.com

作者贡献声明::陈梓娴设计本研究的方案,对稿件重要内容进行了修改;卢嘉慧起草和撰写稿件,获取、分析和解释本研究的数据;杨娜参与数据分析与解释,并对稿件内容进行了修改;陈梓娴获得甘肃省科技计划项目及甘肃省卫生健康行业科研计划项目资助;卢嘉慧获得兰州大学学生创新创业行动计划项目资助。全体作者都同意发表最后的修改稿,同意对本研究的所有方面负责,确保本研究的准确性和诚信。


基金项目: 甘肃省科技计划项目 24JRRA310 甘肃省卫生健康行业科研计划项目 GSWSKY2023-05 兰州大学学生创新创业行动计划项目 20240060182,20250060215
收稿日期:2025-12-29
接受日期:2026-03-09
中图分类号:R445.2  R542.2 
文献标识码:A
DOI: 10.12015/issn.1674-8034.2026.04.025
本文引用格式:卢嘉慧, 杨娜, 陈梓娴. 心脏磁共振评估肥厚型心肌病二尖瓣装置异常的研究进展[J]. 磁共振成像, 2026, 17(4): 175-183. DOI:10.12015/issn.1674-8034.2026.04.025.

0 引言

       肥厚型心肌病(hypertrophic cardiomyopathy, HCM)是一种遗传性心肌病,以左心室心肌非对称性肥厚为主要特征,多数由编码肌小节蛋白的基因突变引起,该病在成人患病率约为1∶500[1]。约70%的HCM患者因二尖瓣前叶收缩期前向运动与室间隔接触,在静息或运动时出现左心室流出道梗阻(left ventricular outflow tract obstruction, LVOTO),其引起的血流动力学异常可导致症状加重、舒张功能障碍、心力衰竭甚至心源性猝死[2]。然而,近年研究表明,二尖瓣装置的结构与功能异常不仅是LVOTO发生的重要促进因素,在某些患者中甚至可能作为独立于室间隔肥厚的原发机制参与疾病进程[3, 4]

       研究表明,HCM并非单纯的心肌疾病,约三分之二的患者同时存在原发性的二尖瓣结构异常,其中以瓣叶(特别是前叶)长度和面积增加(占58%)为主,另有约10%的患者合并独特的乳头肌直接插入瓣叶的先天性畸形[5]。值得注意的是,这些异常在基因阳性但表型阴性(即无明显左室肥厚)的个体中已被发现,强烈提示其属于HCM疾病谱系中的原发性表现,而非继发于心肌肥厚的代偿性改变[6]。因此,早期、精准地评估二尖瓣装置,对于全面认识HCM的病理生理机制、预测梗阻风险及指导个体化干预具有重要的临床意义。

       尽管超声心动图在HCM的二尖瓣装置评估中具有便捷、实时、低成本的优势,但其在空间分辨率、三维解剖显示、组织特征识别及动态机制分析等方面存在明显局限[7]。心脏磁共振(cardiac magnetic resonance, CMR)凭借其无创性、高软组织分辨率及多参数成像的独特优势,已成为评估HCM二尖瓣装置的参考标准[7]。相较于超声心动图,CMR能更清晰地显示二尖瓣叶、腱索及乳头肌的复杂三维解剖结构,精确量化瓣叶长度与乳头肌位置等形态学参数,并可通过钆对比剂延迟强化(late gadolinium enhancement, LGE)与T1 mapping技术评估心肌纤维化程度,从而为探究二尖瓣装置异常与心肌基质改变之间的关联提供可能[8, 9]。这种“一站式”成像能力,在实现HCM全面评估的同时,也为治疗决策的制订、风险分层与预后判断提供了重要依据[10]。然而,现有综述多侧重于CMR技术在HCM中的整体应用[11],或仅聚焦于心肌特征本身[12],尚缺乏专门针对CMR评估二尖瓣装置异常及其与LVOTO机制关联进行系统性梳理的文献。因此,本文系统综述CMR在评估HCM二尖瓣装置形态学异常及其与LVOTO机制相关性方面的研究进展,分析当前研究存在的局限,并展望未来研究方向,以深化对HCM梗阻机制的理解,为疾病的早期识别与个体化治疗提供影像学依据。

1 二尖瓣装置正常结构、功能及CMR表现

       二尖瓣装置(亦称二尖瓣复合体),是由瓣叶、瓣环、腱索和乳头肌构成的精密功能整体,协同实现左心系统血流单向调节[13]。根据Carpentier分类,二尖瓣叶分可为前叶(A1、A2、A3区)、后叶(P1、P2、P3区)与交界区。位于中间扇区的A2与P2区是承受血流冲击并实现有效对合的关键区域。UK Biobank队列数据[14]显示,正常成人二尖瓣前叶长度存在性别差异:男性为(25.0±2.7)mm,女性为(23.1±2.5)mm,一般以28 mm为整体人群正常值上限。CMR多平面长轴电影序列(图1)可清晰显示二尖瓣结构及运动;在三腔心切面舒张期图像上可测量瓣叶长度,正常A2区长约16~24 mm,P2区约为8~14 mm[6]

       二尖瓣环为位于左心房与瓣叶交界处的三维马鞍形纤维环状结构,其形态与面积随心动周期动态变化:舒张期瓣环扩张,瓣口面积增至约4~6 cm2以适应心室充盈;收缩期在左心室收缩作用下,瓣环直径缩小,增强瓣叶对合防止血液反流[15]。通过CMR左心室长轴电影序列可测量二尖瓣环径线(图2),我院78例健康志愿者数据显示,四腔心切面收缩末期瓣环径约20~43 mm、舒张末期约19~42 mm,两腔心切面收缩末期约24~40 mm、舒张末期约21~38 mm。短轴电影序列则可清晰显示不同期相瓣环形态及闭合状态。

       腱索是连接二尖瓣瓣叶与乳头肌的纤维性索状结构,按附着位置可分为三类[16]图3),其具体结构与功能见表1。在薄层(层厚≤3 mm)电影序列图像上,腱索显示为走行规则、附着点明确的细线状低信号;舒张期呈波浪形弯曲,收缩期可出现“摆动征”[17, 18, 19]。高分辨率黑血序列可进一步精确测量腱索直径(正常值一般为1~2 mm)并识别附着点异常。

       二尖瓣乳头肌是二尖瓣装置中的关键动力终端,通过腱索直接牵拉瓣叶,实现瓣膜有效闭合。其起源于左心室壁,主要分为前外侧与后内侧乳头肌:前者位于前壁与侧壁交界处,后者位于下侧壁与下壁交界处。CMR短轴电影序列可清晰评估其大小、位置和数量特征。前外侧乳头肌常较粗大,呈类椭圆形均匀低信号,宽度约11~15 mm,多为单头[23];后内侧乳头肌则常为多头或梳状,多呈结节样低信号(图4)。

图1  CMR 电影序列图像展示二尖瓣Carpentier 解剖分区。1A为四腔心切面电影图像,对应1B中的短轴层面,可观察到MV前叶A3 区与后叶P1 区;1C为两腔心切面电影图像,对应1D中的短轴层面,显示A1区与P3区;1E为三腔心切面电影图像,对应1F 中的短轴层面,显示A2 与P2 区。CMR:心脏磁共振;MV:二尖瓣。
Fig. 1  CMR cine sequence images demonstrating the carpentier anatomical classification of the MV. 1A shows a four-chamber view cine image, corresponding to the short-axis level in 1B, where the A3 segment of MV anterior leaflet and the P1 segment of the posterior leaflet can be observed. 1C presents a two-chamber view cine image, corresponding to the short-axis level in 1D, displaying the A1 and P3 segments. 1E illustrates a three-chamber view cine image, corresponding to the short-axis level in 1F, showing the A2 and P2 segments. CMR: cardiovascular magnetic resonance; MV: mitral valve.
图2  CMR电影序列图像二尖瓣环测量示意图。2A、2B分别为四腔心切面收缩末期及舒张末期:测量线为MV前叶A3区与后叶P1区根部的连线;2C、2D分别为两腔心切面收缩末期及舒张末期:测量线为MV前叶A1区与后叶P3区根部的连线。CMR:心脏磁共振;MV:二尖瓣。
Fig. 2  CMR cine sequence image of MV annulus measurement diagram. 2A, 2B: End-systolic and end-diastolic four-chamber views, with the measurement line connecting the bases of the anterior leaflet A3 segment and the posterior leaflet P1 segment. 2C, 2D: End-systolic and end-diastolic two-chamber views, with the measurement line connecting the bases of the anterior leaflet A1 segment and the posterior leaflet P3 segment. CMR: cardiovascular magnetic resonance; MV: mitral valve.
图3  二尖瓣腱索分级示意图。
Fig. 3  Schematic diagram of mitral valve chordae tendineae classification.
图4  CMR电影序列显示正常人乳头肌结构。CMR:心脏磁共振。
Fig. 4  CMR cine sequence shows normal papillary muscle structure. CMR: cardiovascular magnetic resonance.
表1  二尖瓣腱索的分级、解剖特征与功能
Tab. 1  Classification, anatomical features, and function of MV chordae tendineae

2 HCM患者二尖瓣装置异常

2.1 二尖瓣装置结构异常与梗阻机制的演进认知

       随着影像学与遗传学研究的深入,HCM病理生理机制认知经历了重要演变。既往研究确认左心室肥厚与心肌排列紊乱的核心地位,并阐明二尖瓣前叶在收缩期前向运动(systolic anterior motion, SAM)现象中通过文丘里效应引起LVOTO的关键机制[24, 25]。近年来,研究焦点逐渐转向二尖瓣装置本身的结构异常,其机制与临床意义得到进一步深化。SEITLER等[26]发现SAM现象在亚临床HCM阶段即可出现,提示二尖瓣细微异常在疾病早期已发挥作用。FAVA等[27]通过前瞻性多模态成像研究证实,HCM患者室间隔厚度与二尖瓣前叶长度均显著大于健康对照组,且CMR与超声测量结果高度一致,为术前精准评估提供了数据支持。尤为关键的是,LENTZ CARVALHO等[28]针对副乳头肌等变异进行研究,明确了异常乳头肌的识别与处理是避免术后残余梗阻的重要环节。这些结构改变共同导致收缩期二尖瓣叶所受有效牵拉力下降,使瓣叶更易处于松弛状态,在左室流出道(left ventricular outflow tract, LVOT)高速血流产生的吸引作用下,松弛瓣叶更易被推入流出道,从而诱发或加重SAM及LVOTO,这也解释了患者在负荷状态下更易出现或加重梗阻的现象[29]

2.2 二尖瓣叶冗长

       二尖瓣叶冗长是HCM患者常见的结构性异常,尤其多见于二尖瓣前叶(图5A)。研究显示,HCM患者的前叶平均长度为(26±5)mm,显著高于对照组的(19±5)mm(P<0.001);后叶长度亦明显增加[(14±4)mm vs.(10±3)mm,P<0.001]。若以超过对照组均值2个标准差(即前叶≥30 mm,后叶≥17 mm)为诊断阈值,约34%的HCM患者存在单侧或双侧瓣叶长度异常[6]。SAHOTA等[30]基于1905例HCM患者的CMR数据,通过机器学习证实二尖瓣前叶尖至基底间隔距离、前叶长度与主动脉瓣直径比值、前叶长度与左室内径比值均为LVOTO的独立影像学预测因子,提示了二尖瓣装置的空间位置关系与残余瓣叶结构是独立于室间隔肥厚的梗阻易感标志物。

       二尖瓣前叶冗长通过多种机制参与LVOTO的形成:其一,二尖瓣前叶冗长致瓣体松弛、对合点上移,使其在收缩期更易受到异常血流的攻击[31];其二,因室间隔肥厚导致向后外侧的左室血流直接撞击冗长瓣叶后表面,血流冲击力将其推入流出道,瓣叶-室间隔接触后,流出道压差进一步压闭流出道,梗阻随之加重[32, 33]。值得关注的是,在尚未出现左心室肥厚的HCM致病基因携带者中,已可观察到二尖瓣前叶冗长,提示该异常可能是HCM的早期原发性表型,而非单纯继发于心肌肥厚[6]

       多项研究通过精确量化二尖瓣前叶长度、建立异常诊断阈值,并阐释其在左心室流出道梗阻形成中的流体力学与结构机制,为理解HCM患者二尖瓣装置异常提供了重要的理论与数据基础。然而,该领域的多数研究样本量有限且为单中心回顾性设计,缺乏大规模前瞻性队列验证诊断阈值的普适性与预后价值;且现有测量方法多基于二维影像重建,对瓣叶三维形态(如曲度、面积)及其动态运动模式的评估尚不充分;而瓣叶冗长与心肌纤维化、乳头肌构型等其他基质异常的交互作用仍未明确,其作为独立风险因子或协同因子的权重尚需进一步厘清。

2.3 二尖瓣腱索异常

2.3.1 腱索松弛或冗长

       在HCM患者中,腱索松弛或冗长是常见的二尖瓣结构异常。TROY等[34]对22例梗阻性HCM术中切除的二尖瓣残余瓣叶及附着腱索行组织病理学分析,发现A2区腱索存在显著的松弛、冗长、卷曲及黏液样变性,将瓣叶冗长表型延伸至腱索装置,为二尖瓣装置的原发性异常提供了组织病理学证据。这些异常会减弱收缩期对二尖瓣前叶的有效约束,导致其活动度增加,从而在LVOT高速血流下更易发生前向运动,诱发或加重SAM现象[35]。多项外科与影像学研究[36, 37]表明,异常或松弛的二尖瓣腱索是SAM与LVOTO的重要解剖基础,该情况下若仅行室间隔心肌切除术,术后常易残留梗阻,因此建议同期实施腱索处理等亚瓣下干预措施,以获得更佳的血流动力学效果并改善患者预后。

2.3.2 二级腱索增厚和挛缩

       在HCM患者中,二级腱索是指连接二尖瓣叶体部与乳头肌的腱索结构,其在部分患者中可出现增厚、缩短和纤维化改变[36]。这些异常的二级腱索通过机械牵拉作用,使二尖瓣前叶体部向前移位,形成“帐篷样”结构畸形,显著减少LVOT有效面积,是SAM与LVOTO的重要解剖基础[37, 38]。CMR的薄层电影序列可清晰显示腱索缩短与走行僵直,而LGE序列则有助于识别其在乳头肌或瓣叶附着点区域的局灶性纤维化。

2.3.3 异位腱索

       二尖瓣异位腱索是一种起源于左心室游离壁或室间隔(而非正常乳头肌尖端)的异常纤维结构,其在合并复杂LVOTO的HCM病例中发现率显著增高[39, 40, 41]。该异常结构可直接横跨LVOT,形成机械性梗阻[42];同时,其产生的异常牵拉力也会改变二尖瓣叶运动轨迹,成为 HCM左心室流出道病理性几何形态的重要解剖基础[43]。在CMR电影序列中,可清晰显示异位腱索的异常起源、走行路径及其导致的左心室形态改变(图5B)。

       深化认识腱索松弛、二级腱索增厚挛缩及异位腱索等瓣下结构异常的形态特征及其在SAM与LVOTO形成中的关键机械作用,加深了对梗阻机制的理解,更推动了外科策略从单纯心肌切除术向“室间隔-瓣下装置”联合干预的范式转变,为制订个体化手术方案提供了重要的解剖学依据。然而,当前研究仍存在若干局限:多数结论源自术中观察或回顾性影像分析,缺乏对腱索异常自然史及其动态演变过程的前瞻性研究;且对异常腱索的影像学评估(尤其是CMR)尚未形成统一的量化标准和诊断规范,其与超声测量结果之间的一致性也有待进一步验证;此外,异常腱索与心肌纤维化、基因型及临床表现之间的深层关联尚未被充分阐明,其在疾病表型异质性中的作用机制仍需进一步探索。

2.4 乳头肌异常

2.4.1 乳头肌肥大

       在HCM中,乳头肌肥大是一种特殊表现形式,其诊断标准通常为舒张末期乳头肌最大横径>15 mm,或体积指数>1.1 cm3/m2。根据《中国成人肥厚型心肌病诊断与治疗指南2023》,孤立性乳头肌肥厚已被列为HCM心肌肥厚的五种主要类型之一[44]

       乳头肌肥大主要通过以下两种相互独立的解剖机制导致LVOTO。其一为直接机械性梗阻,BERG等[45]在左心室中部梗阻性肥厚型心肌病病例中证实,肥大的乳头肌可直接挤压收缩期左室中腔,产生动态压力阶差,该机械性梗阻独立于室间隔肥厚及二尖瓣前向运动;其二为间接牵拉性梗阻,USUI等[32]提出前外侧乳头肌头部的前向移位可通过向前牵拉二尖瓣前叶,将其置入左室流出道流场,从而诱发SAM并导致梗阻。而WONG等[46]通过103例手术队列进一步从临床角度显示,异常乳头肌头是促成SAM的关键结构,术中常规予以切除,术后4年随访显示LVOT压差由36.4 mmHg显著降至11 mmHg,SAM相关MR得到有效控制,佐证了移除异常牵拉源即可解除梗阻的病理生理逻辑。CMR电影序列可准确测量乳头肌的径线与体积,为该异常的结构评估提供了可靠影像手段。

2.4.2 异位乳头肌

       异位乳头肌主要表现为起源位置异常,常见向室间隔过度靠近或心尖方向偏移。该异常通过两方面[32, 47]参与LVOTO:一为乳头肌直接插入二尖瓣前叶体部,形成无腱索过渡的刚性连接,收缩期与肥厚室间隔共同构成中腔狭窄区,造成机械性梗阻;二为乳头肌前向移位,改变腱索牵拉几何向量,将二尖瓣前叶向前牵拉或推入流出道,诱发SAM。

       CMR电影序列可清晰显示乳头肌位置偏移,如前外侧乳头肌向室间隔方向移位(与室间距距离<10 mm,图5C)。临床数据[48]证实,HCM患者存在显著的乳头肌前向移位[短轴切面中前外侧乳头肌与室间隔的距离即SXAd:(26.76±6.10)mm vs.(32.10±4.85)mm,P<0.001]。

2.4.3 乳头肌直接插入二尖瓣(肌性连接)

       乳头肌直接插入二尖瓣是一种罕见解剖变异,表现为乳头肌不经过正常腱索结构,而以肌性组织直接与二尖瓣叶体部或基底部融合[49]图5D该异常导致LVOTO的核心机制在于其引起的力学改变[28, 47]:由于缺乏正常腱索的缓冲,乳头肌以肌性组织直接与二尖瓣前叶体部融合,形成刚性“肌性连接”,使乳头肌收缩力直接传递至瓣叶,导致二尖瓣前叶收缩期活动度严重受限并向前位移,从而显著加重SAM现象,另外该异常肌束直接占据流出道空间,与肥厚室间隔共同构成狭窄区,造成动态性腔内梗阻。这种僵直连接从根本上改变了LVOT的血流动力学环境,直接促进了动态梗阻的形成。

2.4.4 乳头肌分叉或融合

       乳头肌分叉指单支乳头肌分裂为多束(图5E),融合则指前外侧与后内侧乳头肌之间出现异常连接。GÜVEN等[50]通过CMR研究证实,双分叉乳头肌是LVOTO的独立形态学预测因子,常与异常腱索附着并存,共同构成梗阻的解剖基础,另外该研究进一步提出并量化了前外侧乳头肌活动度这一功能学指标,发现其与梗阻独立相关,活动度≥57.7%可有效预测梗阻存在,提示乳头肌形态异常可导致其与相邻心肌的收缩协调性改变。而且结合张隽等[51]应用二维斑点追踪技术的发现,HCM患者两乳头肌收缩存在显著不同步,且纵向收缩功能减低,为上述机制提供了直接的定量证据。且HODGES等[52]指出,在梗阻性HCM的外科治疗中,对融合肌桥进行松解或切除是解除复杂型LVOTO的关键步骤。

2.4.5 乳头肌纤维化

       在HCM的病理进程中,乳头肌纤维化表现为一种替代性纤维化,其特征为心肌细胞逐渐被胶原纤维等细胞外基质所取代[24]。其形成机制涉及慢性压力超负荷、微血管缺血及遗传因素等多重病理生理环节[53, 54, 55]。近年研究进一步证实,乳头肌纤维化并非仅出现于疾病晚期,而是HCM早期即可发生的核心病理表型之一。目前关于乳头肌特异性纤维化的检出率尚缺乏大规模研究报告,但整体心肌LGE在HCM中检出率约为50%~80%[56, 57, 58],表明该改变在HCM发生发展中具有普遍性与重要的病理生理意义。

       CMR-LGE序列可直接显示乳头肌纤维化,大规模CMR研究证实,LGE检出的乳头肌纤维化是预测主要不良心脏事件的强有力指标[59]。此外,基于T1 mapping测量的细胞外容积(extracellular volume, ECV)为乳头肌间质性纤维化评估提供了新视角,ECV的预测价值独立于左心室射血分数、室壁厚度、左心室流出道压差以及LGE范围等指标,代表了更早期的纤维化改变,其预测效能甚至优于LGE。

2.4.6 副乳头肌

       副乳头肌是起源于左心室游离壁或室间隔,而非正常乳头肌尖端的异常肌性结构,通常形态较细(直径常<5 mm)(图5F)。TONDI等[60]基于CMR的研究发现,在HCM患者中,原发性副乳头肌的出现率约为5%~7%。其参与LVOTO的机制主要包括:位于LVOT附近的副乳头肌直接参与形成收缩期梗阻;发出异常腱索牵拉并干扰二尖瓣正常闭合;以及改变左心室几何构型,从而加重血流动力学紊乱。另外,TONDI等[61]的研究强调,多模态影像(尤其是CT和CMR)对于识别二尖瓣或乳头肌异常具有关键作用,这些并发异常的存在直接影响手术策略的制定,体现了精准术前评估的重要性。尤其是通过LGE与ECV量化等技术,CMR将评估维度从宏观结构拓展至微观组织病理层面,为临床实现从“解剖识别”到“机制指导治疗”的转变提供了关键依据。

       然而,该领域针对各类乳头肌异常(例如肥大的径线阈值、异位的距离界定)尚未形成国际统一的诊断标准,限制了不同研究之间的可比性;其次,现有证据多基于横断面观察,缺乏对乳头肌异常(特别是纤维化)自然演变轨迹及其与基因型、血流动力学进展关联的前瞻性纵向研究;此外,当前评估多侧重于静态形态与晚期纤维化,而对乳头肌收缩功能、力学特性及其与整体心室协调性的动态交互影响仍认识不足,制约了对梗阻机制更全面的理解。

图5  HCM患者二尖瓣装置异常CMR示意图。5A:三腔心电影序列显示二尖瓣前叶冗长(A2 区长度为 3.31 cm);5B:异位腱索(三腔心电影序列示室间隔至左室心尖的额外纤维结构,黄色箭头所示);5C:异位乳头肌(短轴电影序列示后内侧乳头肌偏离正常附着点、向室间隔移位,黄色箭头所示);5D:乳头肌直接插入二尖瓣(四腔心电影序列示乳头肌与二尖瓣叶无腱索连接,直接附着于二尖瓣前叶根部);5E:乳头肌分叉(四腔心电影序列示乳头肌主干分支为两束);5F:副乳头肌(短轴电影序列示左室腔内起源于室间隔的额外乳头肌结构,黄色箭头所示)。CMR:心脏磁共振;HCM:肥厚型心肌病。
Fig. 5  Schematic CMR illustration of mitral apparatus abnormalities in HCM patients. 5A: Three-chamber cine sequence showing elongated anterior mitral leaflet (length of segment A2 is 3.31 cm); 5B: Ectopic chordae tendineae (three-chamber cine sequence reveals an additional fibrous structure extending from the ventricular septum to the left ventricular apex, indicated by yellow arrow); 5C: Ectopic papillary muscle (short-axis cine sequence shows displacement of the posteromedial papillary muscle from its normal attachment site toward the ventricular septum, indicated by yellow arrow); 5D: Direct insertion of papillary muscle into the mitral valve (four-chamber cine sequence demonstrates papillary muscle attaching directly to the base of the anterior mitral leaflet without chordal connection); 5E: Bifurcated papillary muscle (four-chamber cine sequence shows the main trunk of the papillary muscle splitting into two bundles); 5F: Accessory papillary muscle (short-axis cine sequence reveals an additional papillary muscle structure originating from the ventricular septum within the left ventricular cavity, indicated by yellow arrow). CMR: cardiovascular magnetic resonance; HCM: hypertrophic cardiomyopathy.

3 CMR评估HCM二尖瓣装置异常在治疗策略制定中的价值

       在HCM临床管理中,CMR已从辅助成像手段发展为指导关键治疗决策的核心影像技术。其在精细评估二尖瓣装置解剖及继发性MR方面,相比经胸超声心动图(transthoracic echocardiography, TTE)具有显著优势,为个体化治疗提供了重要依据。

       首先,凭借高空间分辨率与无创组织定征能力,CMR可系统识别TTE可能遗漏的精细解剖异常,包括准确测量二尖瓣叶长度、判断乳头肌肥大与前移、定位异常腱索,并阐明SAM的发生机制,从而清晰揭示LVOTO的解剖基础[4, 53]。另外在功能评估方面,CMR通过相位对比技术定量左室容积、每搏输出量、MR反流量与反流分数的准确性与可重复性已获广泛验证。尤其对于偏心性、多束或动态变化的MR,CMR克服了超声多普勒半定量法的局限,提供更可靠的定量数据[62, 63, 64]

       CMR有助于明确梗阻的主要机制是单纯室间隔肥厚,抑或主要由二尖瓣装置异常驱动[65]。对于后者,若仅行室间隔心肌切除术,常无法完全解除梗阻或纠正MR。CMR图像可直接支持同期进行二尖瓣成形术或乳头肌干预(如复位、松解)的决策,从而避免二次手术[66]。此外,CMR可识别不适合酒精间隔消融的解剖亚型(如梗阻机制与瓣膜装置关系密切相关者),进而引导选择更彻底的外科治疗[67]

       其次,CMR提供的MR定量参数(如反流容积>55 mL,反流分数>40%)以及左室/左房重构指标,是预测症状进展与心功能恶化更敏感的预后标志物[68, 69, 70]。这些客观数据为决定早期手术干预或继续药物随访提供了量化依据,其价值已超越单纯依赖超声的定性或半定量分级。

       最后,CMR凭借其无辐射、可重复性高的特点,成为术后评估残余梗阻、MR程度以及左室反向重构的可靠方法[71],对于指导术后药物治疗及识别需再次干预的患者具有关键作用。

       近年来,CMR在HCM合并MR评估中的核心地位日益获得指南推荐。欧洲心脏病学会与美国心脏协会相关指南专家共识均建议,当超声结果不明确、存在分歧或需精确定量以制定重大治疗决策时,应进行CMR检查[72, 73]。4D Flow CMR等新技术可对LVOT及二尖瓣区的复杂血流模式(如涡流、剪切力)进行可视化与量化分析,为梗阻评估和手术规划提供了新的血流动力学视角[74, 75]

       总之,CMR融合高分辨率解剖成像、精确血流定量及心肌组织特征分析,不仅能系统阐明HCM病理机制,更可直接影响“是否切除心肌”“是否处理瓣膜”“能否进行消融”及“何时干预”等核心临床抉择。在HCM的术前规划、疗效评价与术后随访中,CMR可提供全面而精准的影像学信息,已成为改善患者远期预后不可或缺的重要工具。

4 人工智能辅助评估的进展与瓶颈

       人工智能(artificial intelligence, AI)辅助分析正逐步革新传统测量流程。SAHOTA等[30]开发的基于三腔心脏磁共振图像的机器学习模型,能够自动测量与LVOTO相关的关键参数,其可靠性已接近专家水平,为大规模HCM形态学分析提供了高效工具。然而,该模型在识别精细结构(如二尖瓣前叶)时仍存在局限,这反映了当前AI应用面临的普遍挑战。

       综合现有文献,AI在该领域的主要局限性体现在以下方面:首先,对变异度高的二尖瓣精细结构(如瓣叶、腱索、乳头肌)进行精准识别时,现有算法的准确性与鲁棒性仍有待提升[76]。其次,AI模型常在单中心数据上训练,而真实临床影像因设备、序列等差异存在显著异质性,易导致模型在多中心数据上性能下降,即泛化能力不足。再者,AI决策过程的“黑匣子”特性使其逻辑难以被理解,在高可信度医疗决策中构成障碍[76, 77]。最后,涵盖HCM各亚型的标准化影像数据获取困难,数据资源匮乏制约了高级别模型的开发与验证。

       因此,尽管AI在提升影像评估效率方面潜力巨大,但其临床常规应用仍面临泛化能力不足、可解释性欠缺及训练数据有限等多重挑战[78]。未来的发展有赖于构建大规模多中心标准化数据库、开发更鲁棒可解释性的算法,并通过前瞻性研究验证其临床价值。

5 小结与展望

       CMR凭借多参数成像优势,揭示了瓣叶冗长、腱索及乳头肌异常等构成独立于室间隔肥厚的梗阻解剖基础。这些异常通过改变瓣叶牵拉力、占据流出道等机制诱发SAM及LVOTO。CMR构建的“解剖—功能—组织”一体化体系,深化了机制理解并指导了临床全流程管理。

       尽管基于CMR的研究已显著深化了对HCM的认识,但当前领域内仍面临诸多瓶颈:关键参数缺乏统一量化阈值,阻碍标准化推广;现有结论多源于回顾性研究,缺乏前瞻性纵向数据追踪其自然演变史;研究侧重静态形态学,对瓣膜动态力学特性及交互影响认识不足;AI模型鲁棒性与可解释性仍有欠缺。

       针对上述问题,未来需向整合性与精准化发展。在研究层面,应建立多中心前瞻性队列,构建标准化评估体系,明确解剖异常的预后价值。在技术层面,需促进多模态影像与AI深度融合,实现瓣叶三维动力学、腱索生物力学及乳头肌功能的动态量化。最终有望通过整合基因型、细胞力学与心室功能数据,将HCM的诊疗从静态解剖描述,向预测性力学功能评估转型,从而推动个体化精准治疗。

[1]
MÖBIUS-WINKLER M N, LAUFS U, LENK K. The diagnosis and treatment of hypertrophic cardiomyopathy[J]. Dtsch Arztebl Int, 2024, 121(24): 805-811. DOI: 10.3238/arztebl.m2024.0196.
[2]
崔颢, 来永强. 肥厚型梗阻性心肌病中的二尖瓣: 现状与争议[J]. 临床外科杂志, 2023, 31(9): 804-807. DOI: 10.3969/j.issn.1005-6483.2023.09.002.
CUI H, LAI Y Q. Mitral valve in hypertrophic obstructive cardiomyopathy: Status and controversy[J]. J Clin Surg, 2023, 31(9): 804-807. DOI: 10.3969/j.issn.1005-6483.2023.09.002.
[3]
SAKELLAROPOULOS S, SVAB S, MOHAMMED M, et al. The role of mitral valve in hypertrophic obstructive cardiomyopathy: an updated review[J/OL]. Curr Probl Cardiol, 2021, 46(3): 100641 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/32586596/. DOI: 10.1016/j.cpcardiol.2020.100641.
[4]
HERMIDA U, STOJANOVSKI D, RAMAN B, et al. Left ventricular anatomy in obstructive hypertrophic cardiomyopathy: beyond basal septal hypertrophy[J]. Eur Heart J Cardiovasc Imaging, 2023, 24(6): 807-818. DOI: 10.1093/ehjci/jeac233.
[5]
KLUES H G, MARON B J, DOLLAR A L, et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy[J]. Circulation, 1992, 85(5): 1651-1660. DOI: 10.1161/01.cir.85.5.1651.
[6]
MARON M S, OLIVOTTO I, HARRIGAN C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy[J]. Circulation, 2011, 124(1): 40-47. DOI: 10.1161/CIRCULATIONAHA.110.985812.
[7]
中华医学会心血管病学分会影像学组, 中国医师协会放射医师分会心血管专业委员会. 无创性心血管影像学技术临床适用标准中国专家共识[J]. 中华心血管病杂志, 2020, 48(11): 906-921. DOI: 10.3760/cma.j.cn112148-20200413-00309.
Imaging Group of the Cardiovascular Disease Branch of the Chinese Medical Association, Cardiovascular Professional Committee of the Radiology Branch of the Chinese Medical Association. Chinese expert consensus on the clinical appropriate use criteria of non-invasive cardiovascular imaging modalities[J]. Chin J Cardiol, 2020, 48(11): 906-921. DOI: 10.3760/cma.j.cn112148-20200413-00309.
[8]
GARBIN H I, FOPPA M, BIOLO A, et al. Left atrial late gadolinium enhancement and atrial fibrillation in hypertrophic cardiomyopathy[J/OL]. Heart Rhythm, 2025, 22(12): e1241-e1247 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/40784418/. DOI: 10.1016/j.hrthm.2025.08.008.
[9]
ZHI Y, ZHANG T Y, GUI F D, et al. Myocardial fibrosis evaluated by T1 mapping and its relationship to left ventricular hypertrophy, strain, and T2 value in hypertrophic cardiomyopathy without late gadolinium enhancement[J/OL]. J Thorac Imaging, 2025 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/41084187/. DOI: 10.1097/RTI.0000000000000862.
[10]
宋燕燕, 陆敏杰, 赵世华. 心血管MRI用于二尖瓣病变进展[J]. 中国医学影像技术, 2024, 40(2): 290-293. DOI: 10.13929/j.issn.1003-3289.2024.02.028.
SONG Y Y, LU M J, ZHAO S H. Application progresses of cardiovascular MRI in mitral valve diseases[J]. Chin J Med Imaging Technol, 2024, 40(2): 290-293. DOI: 10.13929/j.issn.1003-3289.2024.02.028.
[11]
唐雍淇, 娜孜拉·努尔兰, 迪丽努尔·买买提依明. 肥厚型心肌病的诊断及治疗研究进展[J]. 临床医学进展, 2023, 13(9): 14695-14700. DOI: 10.12677/ACM.2023.1392054.
TANG Y Q, NUERLAN N, MAIMAITI YIMING D. Research progress in the diagnosis and treatment of HCM[J]. Adv Clin Med, 2023, 13(9): 14695-14700. DOI: 10.12677/ACM.2023.1392054.
[12]
杨粤龙, 罗心仪, 罗若泓, 等. 心脏磁共振定量技术在心肌病变评估中的应用与进展[J]. 中国医师杂志, 2024, 26(1): 1-5. DOI: 10.3760/cma.j.cn431274-20240101-00001.
YANG Y L, LUO X Y, LUO R H, et al. Application and progress of cardiac magnetic resonance quantitative technology in the evaluation of myocardial lesions[J]. J Chin Physician, 2024, 26(1): 1-5. DOI: 10.3760/cma.j.cn431274-20240101-00001.
[13]
POPA M O, IRIMIA A M, PAPAGHEORGHE M N, et al. The mechanisms, diagnosis and management of mitral regurgitation in mitral valve prolapse and hypertrophic cardiomyopathy[J/OL]. Discoveries (Craiova), 2016, 4(2): e61 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/32309580/. DOI: 10.15190/d.2016.8.
[14]
RICCI F, AUNG N, GALLINA S, et al. Cardiovascular magnetic resonance reference values of mitral and tricuspid annular dimensions: the UK Biobank cohort[J/OL]. J Cardiovasc Magn Reson, 2020, 23(1): 5 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/33407573/. DOI: 10.1186/s12968-020-00688-y.
[15]
TUMENAS A, TAMKEVICIUTE L, ARZANAUSKIENE R, et al. Multimodality imaging of the mitral valve: morphology, function, and disease[J]. Curr Probl Diagn Radiol, 2021, 50(6): 905-924. DOI: 10.1067/j.cpradiol.2020.09.013.
[16]
LAM J H C, RANGANATHAN N, WIGLE E D, et al. Morphology of the human mitral valve: I. chordae tendineae: a new classification[J]. Circulation, 1970, 41(3): 449-458. DOI: 10.1161/01.cir.41.3.449.
[17]
MAFFESSANTI F, GRIPARI P, PONTONE G, et al. Three-dimensional dynamic assessment of tricuspid and mitral annuli using cardiovascular magnetic resonance[J]. Eur Heart J Cardiovasc Imaging, 2013, 14(10): 986-995. DOI: 10.1093/ehjci/jet004.
[18]
KHALIGHI A H, DRACH A, BLOODWORTH C H 4th, et al. Mitral valve chordae tendineae: topological and geometrical characterization[J]. Ann Biomed Eng, 2017, 45(2): 378-393. DOI: 10.1007/s10439-016-1775-3.
[19]
SABBAG A, ESSAYAGH B, BARRERA J D R, et al. EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on valvular heart disease and the European Association of Cardiovascular Imaging endorsed cby the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society[J]. Europace, 2022, 24(12): 1981-2003. DOI: 10.1093/europace/euac125.
[20]
JEDRZEJCZYK J H, CARLSON HANSE L, JAVADIAN S, et al. Mitral annular forces and their potential impact on annuloplasty ring selection[J/OL]. Front Cardiovasc Med, 2021, 8: 799994 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/35059450/. DOI: 10.3389/fcvm.2021.799994.
[21]
CALAFIORE A M, PRAPAS S, TOTARO A, et al. Cutting the second order chords during mitral valve repair[J]. J Card Surg, 2022, 37(12): 4072-4078. DOI: 10.1111/jocs.17194.
[22]
NEEMA P K, PANIDAPU N. The mechanisms and pathophysiology of mitral regurgitation: a narrative review[J]. Ann Card Anaesth, 2025, 28(2): 109-118. DOI: 10.4103/aca.aca_221_24.
[23]
RAJIAH P, FULTON N L, BOLEN M. Magnetic resonance imaging of the papillary muscles of the left ventricle: normal anatomy, variants, and abnormalities[J/OL]. Insights Imaging, 2019, 10(1): 83 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/31428880/. DOI: 10.1186/s13244-019-0761-3.
[24]
MARON M S, ROWIN E J, MARON B J. How to image hypertrophic cardiomyopathy[J/OL]. Circ Cardiovasc Imaging, 2017, 10(7): e005372 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/28701526/. DOI: 10.1161/CIRCIMAGING.116.005372.
[25]
李碧兰, 谢林, 李娅姣, 等. 肥厚型梗阻性心肌病中的二尖瓣处理策略及争议[J]. 中国胸心血管外科临床杂志, 2024, 31(8): 1242-1248. DOI: 10.7507/1007-4848.202312036.
LI B L, XIE L, LI Y J, et al. Mitral valve management in hypertrophic obstructive cardiomyopathy and its controversies[J]. Chin J Clin Thorac Cardiovasc Surg, 2024, 31(8): 1242-1248. DOI: 10.7507/1007-4848.202312036.
[26]
SEITLER S, DE ZOYSA ANTHONY S, OBIANYO C C C, et al. Systolic anterior motion of the anterior mitral valve leaflet begins in subclinical hypertrophic cardiomyopathy[J]. Eur Heart J Cardiovasc Imaging, 2023, 25(1): 86-94. DOI: 10.1093/ehjci/jead186.
[27]
FAVA A M, MEHTA A R, BAUER A, et al. Measurements of the interventricular septum and mitral leaflet length in hypertrophic cardiomyopathy patients who underwent surgical myectomy: a prospective comparative multimodality imaging study[J/OL]. Am J Cardiol, 2024, 227: 48-56 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39094946/. DOI: 10.1016/j.amjcard.2024.07.034.
[28]
LENTZ CARVALHO J, SCHAFF H V, MORRIS C S, et al. Anomalous papillary muscles-Implications in the surgical treatment of hypertrophic obstructive cardiomyopathy[J/OL]. J Thorac Cardiovasc Surg, 2022, 163(1): 83-89.e1 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/32414597/. DOI: 10.1016/j.jtcvs.2020.04.007.
[29]
GUIGUI S A, TORRES C, ESCOLAR E, et al. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review[J]. J Thorac Dis, 2022, 14(6): 2309-2325. DOI: 10.21037/jtd-22-182.
[30]
SAHOTA M, SARASKANI S R, XU H, et al. Machine learning evaluation of LV outflow obstruction in hypertrophic cardiomyopathy using three-chamber cardiovascular magnetic resonance[J]. Int J Cardiovasc Imaging, 2022, 38(12): 2695-2705. DOI: 10.1007/s10554-022-02724-7.
[31]
高一鸣, 段福建, 逄坤静, 等. 肥厚型梗阻性心肌病患者二尖瓣叶长度及对合形态异常的超声心动图随访研究[J]. 中国循环杂志, 2020, 35(4): 379-383. DOI: 10.3969/j.issn.1000-3614.2020.04.011.
GAO Y M, DUAN F J, PANG K J, et al. Changes on the prolonged leaflets and abnormal tenting morphology of mitral valve in patients with hypertrophic obstructive cardiomyopathy post septal myectomy[J]. Chin Circ J, 2020, 35(4): 379-383. DOI: 10.3969/j.issn.1000-3614.2020.04.011.
[32]
USUI A, MUTSUGA M. Surgical management for systolic anterior motion (SAM) of the mitral valve in obstructive hypertrophic myopathy[J]. Ann Thorac Cardiovasc Surg, 2022, 28(4): 239-248. DOI: 10.5761/atcs.ra.22-00103.
[33]
WU Z H, XIE L, LI Y J, et al. Mitral valve in obstructive hypertrophic cardiomyopathy: abnormalities, management and controversies[J/OL]. Rev Cardiovasc Med, 2023, 24(9): 246 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39076404/. DOI: 10.31083/j.rcm2409246.
[34]
TROY A L, NARULA N, MASSERA D, et al. Histopathology of the mitral valve residual leaflet in obstructive hypertrophic cardiomyopathy[J/OL]. JACC Adv, 2023, 2(3): 100308 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/37383048/. DOI: 10.1016/j.jacadv.2023.100308.
[35]
OGUNMUYIWA O, RELLECKE P, LICHTENBERG A, et al. Muscular mitral chord contribution to left ventricular outflow tract obstruction in HOCM[J/OL]. Thorac Cardiovasc Surg Rep, 2019, 8(1): e18-e19 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/31211027/. DOI: 10.1055/s-0039-1692155.
[36]
HAYASHI H, SINGH S K, HAHN R T, et al. Mitral regurgitation mechanisms related to systolic anterior motion in hypertrophic cardiomyopathy[J]. J Thorac Dis, 2024, 16(1): 26-39. DOI: 10.21037/jtd-23-1206.
[37]
GHARIBEH L, SMEDIRA N G, GRAU J B. Comprehensive left ventricular outflow tract management beyond septal reduction to relieve obstruction[J]. Asian Cardiovasc Thorac Ann, 2022, 30(1): 43-52. DOI: 10.1177/02184923211034689.
[38]
RAM E, SCHWAMMENTHAL E, KUPERSTEIN R, et al. Secondary chordal resection with septal myectomy for treatment of symptomatic obstructive hypertrophic cardiomyopathy[J]. Eur J Cardiothorac Surg, 2021, 60(3): 699-707. DOI: 10.1093/ejcts/ezab116.
[39]
HAMMAMI R, KAMMOUN A, HASSINE M, et al. Hypertrophic obstructive cardiomyopathy with left ventricle outflow tract chordae insertion: Surgery or alcohol septal ablation A case report[J/OL]. Clin Case Rep, 2023, 11(9): e7928 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/37744623/. DOI: 10.1002/ccr3.7928.
[40]
YASIN A, TRONGTORSAK A, SHAH S, et al. Aberrant chordae tendineae causing transient left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J/OL]. J Am Coll Cardiol, 2024, 83(13): 4218 [2025-12-28]. https://www.jacc.org/doi/10.1016/S0735-1097(24)06208-9. DOI: 10.1016/S0735-1097(24)06208-9.
[41]
KADKHODAYAN A, SCHAFF H V, ELEID M F. Anomalous papillary muscle insertion in hypertrophic cardiomyopathy[J/OL]. Eur Heart J Cardiovasc Imaging, 2016, 17(5): 588 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/26864188/. DOI: 10.1093/ehjci/jew007.
[42]
CITTADINI F, OLIVA A, ARENA V, et al. Sudden cardiac death due to an anomalous posterior papillary muscle[J]. Am J Forensic Med Pathol, 2011, 32(3): 239-241. DOI: 10.1097/PAF.0b013e3181d3ca7e.
[43]
RAFFA G M, ROMANO G, TURRISI M, et al. Pathoanatomic findings and treatment during hypertrophic obstructive cardiomyopathy surgery: the role of mitral valve[J]. Heart Lung Circ, 2019, 28(3): 477-485. DOI: 10.1016/j.hlc.2018.02.006.
[44]
国家心血管病中心心肌病专科联盟, 中国医疗保健国际交流促进会心血管病精准医学分会"中国成人肥厚型心肌病诊断与治疗指南2023"专家组. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志. 2023. 38(1): 1-33. DOI: 10.3969/j.issn.1000-3614.2023.01.001.
The Joint Committee of Cardiomyopathy Specialty Alliance, National Center for Cardiovascular Diseases/Cardiovascular Precision Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care. "2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy". 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy[J]. Chinese Circulation Journal. 2023. 38(1): 1-33. DOI: 10.3969/j.issn.1000-3614.2023.01.001
[45]
BERG J J, ECKSTEIN J, DEUTSCH M A, et al. Resection of hypertrophic papillary muscles and mitral valve replacement in a patient with midventricular hypertrophic obstructive cardiomyopathy - a new approach[J/OL]. J Cardiothorac Surg, 2024, 19(1): 105 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/38388907/. DOI: 10.1186/s13019-024-02529-w.
[46]
WONG L Y, VILA R, LANTZ G, et al. Midterm outcomes: a comprehensive approach to surgery for hypertrophic obstructive cardiomyopathy[J]. Ann Thorac Surg, 2024, 118(3): 597-603. DOI: 10.1016/j.athoracsur.2024.05.024.
[47]
KAWAGOE K, FURUKAWA K, ISHI H, et al. Surgical management of hypertrophic obstructive cardiomyopathy with anomalous papillary muscle: a case report[J]. J Cardiol Cases, 2025, 31(4): 101-104. DOI: 10.1016/j.jccase.2024.12.006.
[48]
GILREATH K, SAWMA T, SCHAFF H, et al. Abstract 4363343: papillary muscle anatomy in hypertrophic cardiomyopathy: comparison to normal and impact on outcomes of septal myectomy[J/OL]. Circulation, 2025, 152(Suppl_3) [2025-12-28]. https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4363343. DOI: 10.1161/circ.152.suppl_3.4363343.
[49]
LEKOVIĆ A, ŽIVKOVIĆ V, NIKOLIĆ S. Anomalous papillary muscle insertion into mitral valve leaflet: Autopsy study and implications[J]. J Forensic Sci, 2023, 68(1): 176-184. DOI: 10.1111/1556-4029.15182.
[50]
GÜVEN B, CAN T S, DENIZ M F, et al. Evaluation of potential links between phenotypic features and genetic variants in left ventricular outflow tract obstruction in hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging[J]. Int J Cardiovasc Imaging, 2024, 40(11): 2417-2428. DOI: 10.1007/s10554-024-03250-4.
[51]
张隽, 邓又斌, 汤乔颖, 等. 二维斑点追踪技术评价肥厚型心肌病患者左心室各层心肌的收缩功能[J]. 中华超声影像学杂志, 2015, 24(4): 277-281. DOI: 10.3760/cmaj.i.ssn1.004-44772.0150.40.01.
ZHANG J, DENG Y B, TANG Q Y, et al. Evaluation of left ventricular systolic function in different layers myocardium in patients with hypertrophic cardiomyopathy by two-dimensional speckle tracking echocardiography[J]. Chin J Ultrason, 2015, 24(4): 277-281. DOI: 10.3760/cmaj.i.ssn1.004-44772.0150.40.01.
[52]
HODGES K, RIVAS C G, AGUILERA J, et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center[J]. J Thorac Cardiovasc Surg, 2019, 157(6): 2289-2299. DOI: 10.1016/j.jtcvs.2018.11.148.
[53]
SCHLITTLER M, PRAMSTALLER P P, ROSSINI A, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts[J/OL]. Int J Mol Sci, 2023, 24(19): 14845 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/37834293/. DOI: 10.3390/ijms241914845.
[54]
SKÓRKA P, PIOTROWSKI J, BAKINOWSKA E, et al. The role of signalling pathways in myocardial fibrosis in hypertrophic cardiomyopathy[J/OL]. Rev Cardiovasc Med, 2025, 26(2): 27152 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/40026508/. DOI: 10.31083/RCM27152.
[55]
MURTHI S RAJ, PETRY A, SHASHIKADZE B, et al. Contribution of hypoxia-inducible factor 1alpha to pathogenesis of sarcomeric hypertrophic cardiomyopathy[J/OL]. Sci Rep, 2025, 15(1): 2132 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39820339/. DOI: 10.1038/s41598-025-85187-9.
[56]
KAMP N J, CHERY G, KOSINSKI A S, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis[J/OL]. Prog Cardiovasc Dis, 2021, 66: 10-16 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/33171204/. DOI: 10.1016/j.pcad.2020.11.001.
[57]
NAKAMORI S, ROWIN E J, JAAFAR N, et al. Abstract 16842: progression of myocardial fibrosis in hypertrophic cardiomyopathy[J/OL]. Circulation, 2023, 148(Suppl_1) [2025-12-28]. https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.16842. DOI: 10.1161/circ.148.suppl_1.16842.
[58]
ONG L T, FAN S W D. Prevalence and clinical significance of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy: a systematic review and meta-analysis[J]. Cardiol Young, 2024, 34(7): 1456-1465. DOI: 10.1017/S1047951124000337.
[59]
KIAOS A, DASKALOPOULOS G N, KAMPERIDIS V, et al. Quantitative late gadolinium enhancement cardiac magnetic resonance and sudden death in hypertrophic cardiomyopathy: a meta-analysis[J]. JACC Cardiovasc Imaging, 2024, 17(5): 489-497. DOI: 10.1016/j.jcmg.2023.07.005.
[60]
TONDI D, STURLA F, MARIN-CUARTAS M, et al. Magnetic resonance-based computational modelling of healthy and prolapsing mitral valves to quantify the load transfer between the mitral apparatus and the ventricular myocardium[J/OL]. Comput Methods Programs Biomed, 2026, 274: 109151 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/41265362/. DOI: 10.1016/j.cmpb.2025.109151.
[61]
KOO H J, LEE S A, JUNG S H, et al. Tailored planning of surgical myectomy in obstructive hypertrophic cardiomyopathy[J/OL]. Radiographics, 2024, 44(1): e230050 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/38060425/. DOI: 10.1148/rg.230050.
[62]
BAESSATO F, FUSINI L, MURATORI M, et al. Echocardiography vs. CMR in the quantification of chronic mitral regurgitation: a happy marriage or stormy divorce [J/OL]. J Cardiovasc Dev Dis, 2023, 10(4): 150 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/37103029/. DOI: 10.3390/jcdd10040150.
[63]
GARG P, PAVON A G, PENICKA M, et al. Cardiovascular magnetic resonance imaging in mitral valve disease[J]. Eur Heart J, 2025, 46(7): 606-619. DOI: 10.1093/eurheartj/ehae801.
[64]
BOTIS I, BAZMPANI M A, DAIOS S, et al. The role of cardiovascular magnetic resonance imaging in the assessment of mitral regurgitation[J/OL]. Diagnostics (Basel), 2024, 14(6): 644 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/38535064/. DOI: 10.3390/diagnostics14060644.
[65]
TONDI L, DISABATO G, D'ANDRIA P, et al. Cardiovascular magnetic resonance insights into anomalies of the mitral valve apparatus in Fabry cardiomyopathy and hypertrophic cardiomyopathy[J/OL]. Front Cardiovasc Med, 2024, 11: 1458705 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39411176/. DOI: 10.3389/fcvm.2024.1458705.
[66]
PUGLIESE L, LUCIANO A, CHIOCCHI M. The role of cardiac magnetic resonance imaging in the management of hypertrophic cardiomyopathy[J/OL]. J Cardiovasc Dev Dis, 2025, 12(5): 189 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/40422960/. DOI: 10.3390/jcdd12050189.
[67]
ROWIN E J, MARON B J, MARON M S. The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications[J]. JACC Cardiovasc Imaging, 2020, 13(9): 2002-2016. DOI: 10.1016/j.jcmg.2019.09.020.
[68]
PAVON A G, GUGLIELMO M, MENNILLI P M, et al. The role of cardiovascular magnetic resonance in patients with mitral regurgitation[J/OL]. J Cardiovasc Dev Dis, 2022, 9(11): 399 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/36421934/. DOI: 10.3390/jcdd9110399.
[69]
MYERSON S G, D'ARCY J, CHRISTIANSEN J P, et al. Determination of clinical outcome in mitral regurgitation with cardiovascular magnetic resonance quantification[J]. Circulation, 2016, 133(23): 2287-2296. DOI: 10.1161/CIRCULATIONAHA.115.017888.
[70]
MAHER T, VEGH A, URETSKY S. Mitral regurgitation: advanced imaging parameters and changing treatment landscape[J]. Heart Fail Clin, 2023, 19(4): 525-530. DOI: 10.1016/j.hfc.2023.05.001.
[71]
GARG P, SWIFT A J, ZHONG L, et al. Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging[J]. Nat Rev Cardiol, 2020, 17(5): 298-312. DOI: 10.1038/s41569-019-0305-z.
[72]
COISNE A, LANCELLOTTI P, HABIB G, et al. ACC/AHA and ESC/EACTS guidelines for the management of valvular heart diseases JACC guideline comparison[J]. J Am Coll Cardiol, 2023, 82(8): 721-734. DOI: 10.1016/j.jacc.2023.05.061.
[73]
THOMPSON A, FLEISCHMANN K E, SMILOWITZ N R, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J/OL]. Circulation, 2024, 150(19) [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39316661/. DOI: 10.1161/cir.0000000000001285.
[74]
GUPTA A N, AVERY R, SOULAT G, et al. Direct mitral regurgitation quantification in hypertrophic cardiomyopathy using 4D flow CMR jet tracking: evaluation in comparison to conventional CMR[J/OL]. J Cardiovasc Magn Reson, 2021, 23(1): 138 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/34865629/. DOI: 10.1186/s12968-021-00828-y.
[75]
LEE J, GUPTA A N, MA L E, et al. Valvular regurgitation flow jet assessment using in vitro 4D flow MRI: Implication for mitral regurgitation[J]. Magn Reson Med, 2022, 87(4): 1923-1937. DOI: 10.1002/mrm.29082.
[76]
余妙如, 张德富, 曾伟, 等. 人工智能在心脏多模态影像中的应用[J]. 临床心血管病杂志, 2023, 39(12): 922-929. DOI: 10.13201/j.issn.1001-1439.2023.12.005.
YU M R, ZHANG D F, ZENG W, et al. Advances in the application of artificial intelligence in multimodality cardiac imaging[J]. J Clin Cardiol, 2023, 39(12): 922-929. DOI: 10.13201/j.issn.1001-1439.2023.12.005.
[77]
谢明星. 医学影像人工智能在心脏瓣膜疾病介入诊疗中的应用[J]. 临床心血管病杂志, 2022, 38(12): 929-933, 940. DOI: 10.13201/j.issn.1001-1439.2022.12.001.
XIE M X. Artificial intelligence in medical imaging: implications for interventional therapy of heart valve diseases[J]. J Clin Cardiol, 2022, 38(12): 929-933, 940. DOI: 10.13201/j.issn.1001-1439.2022.12.001.
[78]
王建安. 人工智能赋能心血管疾病影像学评估[J]. 中国心血管杂志, 2025, 30(2): 121-122. DOI: 10.3969/j.issn.1007-5410.2025.02.001.
WANG J A. Artificial intelligence enhances imaging assessment in cardiovascular diseases,[J]. Chin J Cardiovasc Med, 2025, 30(2): 121-122. DOI: 10.3969/j.issn.1007-5410.2025.02.001.

上一篇 鼻咽癌代谢成像技术研究进展:从机制到应用
下一篇 多参数MRI及影像组学区分乳腺癌HER-2低表达和零表达状态的研究进展
  
诚聘英才 | 广告合作 | 免责声明 | 版权声明
联系电话:010-67113815
京ICP备19028836号-2